News argenx SE

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Real-time Euronext Bruxelles Other stock markets 14:28:00 09/12/2025 GMT			5-day change	1st Jan Change
774.40 ^EUR	-1.17%		-0.90%	+29.07%

12-04	KBC Securities Upgrades Argenx to Buy, Boosts PT	MT
12-02	European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading	MT

KBC Securities Upgrades Argenx to Buy, Boosts PT	12-04	MT
European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading	12-02	MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	12-01	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Gain 4% for Week	11-28	MT
Wolfe Research Downgrades argenx to Peer Perform From Outperform	11-24	MT
Argenx announces results of extraordinary general meeting of shareholders	11-18	RE
Argenx Announces Results of Extraordinary General Meeting of Shareholders	11-18	GL
Wedbush Raises Price Target on argenx to $1,000 From $880, Keeps Outperform Rating	11-14	MT
Argenx : FMR LLC - argenx SE - Breda	11-06	PU
Denali Therapeutics Inc. Announces Board and Executive Changes	11-06	CI
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	11-06	MT
Argenx Gets Health Canada Approval for CIDP Treatment Vyvgart SC	11-05	MT
/C O R R E C T I O N from source -- argenx Canada Inc./	11-05	AQ
Argenx SE Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada	11-05	CI
Argenx SE, Q3 2025 Earnings Call, Oct 30, 2025	10-30
Argenx SE Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	10-30	CI
Argenx Q3 Earnings, Operating Income Rise; Shares Up Pre-Bell	10-30	MT
Argenx : argenx Reports Third Quarter 2025 Financial Results and Provides Business Update	10-30	PU
Argenx SE Q3 net income USD 344.258 million	10-30	RE
Argenx : argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients	10-30	PU
Argenx Reports Third Quarter 2025 Financial Results and Provides Business Update	10-30	GL
Corporate earnings calendar for October 30, 2025: Schneider and TotalEnergies ahead of Amazon and Apple	10-29
Argenx SE Presents New Data At AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients	10-29	CI
Argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients	10-29	GL
Earnings calendar for October 27-31: Apple, Microsoft, Amazon, and others report	10-27

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News argenx SE

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Filters